Testing oral semaglutide for Alzheimer's disease
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests whether an oral diabetes medicine called semaglutide can help people with mild-to-moderate Alzheimer's disease. It may work by reducing inflammation or protecting brain cells, and researchers want to see if it slows memory loss.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with Alzheimer's disease by a doctor
- You are at least 50 years old
- Your thinking and memory test (MMSE) score is 18 or higher
- You have a friend or family member who can check in with you regularly during the study
- You do not have type 2 diabetes that would require switching your medicine to semaglutide
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if a combination of insulin and semaglutide (a diabetes drug) can improve memory and thinking in people with mild cognitive impairment (MCI) who also have metabolic syndrome (a cluster of health issues like large waist, high blood sugar, and high blood pressure). It aims to see if treating blood sugar problems helps protect the brain.
This trial tests whether galcanezumab, an antibody injection, can help people with mild-to-moderate Alzheimer's disease. It is for patients who have a confirmed Alzheimer's diagnosis and a caregiver who can support them.
This study tests whether a new medicine can improve blood vessel and insulin function in the brain while you continue your current Alzheimer's drug (lecanemab or donanemab). It may help the anti-amyloid therapy work better and slow down memory loss.
This trial tests a new approach to treating Alzheimer's disease by improving both treatment and monitoring. It may help people with mild to moderate Alzheimer's who have specific brain changes seen on scans and in spinal fluid tests.
This study tests whether two drugs—IL-2 (an immune-boosting medication) and semaglutide (a diabetes drug that may help brain function)—can slow memory loss in people with Alzheimer's disease. Researchers believe these drugs together might help reduce brain inflammation and protect memory.
This trial tests whether semaglutide changes blood flow in the brain and the brain’s “barrier” (how well the brain is protected) in people with type 2 diabetes. It may help researchers understand brain-related effects of diabetes treatment using scans and blood tests.
Hear when a new Alzheimer Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.